Add Yahoo as a preferred source to see more of our stories on Google. DOTHAN, Ala (WDHN) – Sen. Katie Britt (R-Ala.) joined four other U.S. senators to introduce the CLEAR LABELS Act Tuesday, an act ...

Federal law requires every prescription drug to include a document describing dosing guidelines, contraindications, results from clinical trials and safety considerations. But a spate of recent court ...

The Supreme Court on Jan. 16, 2026, agreed to decide a case about how generic companies can communicate to the market about their products, including whether their product promotion may infringe ...

This article originally appeared on ProPublica. Senators introduced legislation on Thursday that would require prescription drug labels to identify where the medication was made, adding momentum to a ...

The U.S. Supreme Court hears arguments today in a case that could mean a lot to drug companies and consumers. Drug firms have been seeking a legal shield from consumer lawsuits. The pharmaceutical ...

Children with primary immunodeficiencies often had drug allergy labels, almost all of which were not confirmed when evaluated ...

The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drug maker Hikma that puts so-called “skinny labels” back in the spotlight. The high court has agreed to make the ...

Obesity can alter the action of many types of medications in ways affecting safety and/or efficacy, but this often isn’t mentioned in the labels. Experts in obesity and pharmacology are trying to ...

Bruce Huang of Saint Island International Patent & Law Offices explains how the Intellectual Property and Commercial Court and the Supreme Court have recently clarified limits on generic drug skinny-l ...

With a look at 160 common medications, about one out of every five are prescribed off-label, according to recent research. This means that the drugs were used in ways never approved by the FDA.

Participants examined the challenges and opportunities to update oncology drug labeling that is inconsistent with the current evidence base and use in clinical practice. Discussions focused on what ...